These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 19527031)

  • 1. Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics.
    Keough DT; Hocková D; Holý A; Naesens LM; Skinner-Adams TS; Jersey Jd; Guddat LW
    J Med Chem; 2009 Jul; 52(14):4391-9. PubMed ID: 19527031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of novel N-branched acyclic nucleoside phosphonates as potent and selective inhibitors of human, Plasmodium falciparum and Plasmodium vivax 6-oxopurine phosphoribosyltransferases.
    Hocková D; Keough DT; Janeba Z; Wang TH; de Jersey J; Guddat LW
    J Med Chem; 2012 Jul; 55(13):6209-23. PubMed ID: 22725979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of branched 9-[2-(2-phosphonoethoxy)ethyl]purines as a new class of acyclic nucleoside phosphonates which inhibit Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.
    Hocková D; Holý A; Masojídková M; Keough DT; de Jersey J; Guddat LW
    Bioorg Med Chem; 2009 Sep; 17(17):6218-32. PubMed ID: 19666228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acyclic nucleoside phosphonates containing a second phosphonate group are potent inhibitors of 6-oxopurine phosphoribosyltransferases and have antimalarial activity.
    Keough DT; Špaček P; Hocková D; Tichý T; Vrbková S; Slavětínská L; Janeba Z; Naesens L; Edstein MD; Chavchich M; Wang TH; de Jersey J; Guddat LW
    J Med Chem; 2013 Mar; 56(6):2513-26. PubMed ID: 23448281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of purine N9-[2-hydroxy-3-O-(phosphonomethoxy)propyl] derivatives and their side-chain modified analogs as potential antimalarial agents.
    Krečmerová M; Dračínský M; Hocková D; Holý A; Keough DT; Guddat LW
    Bioorg Med Chem; 2012 Feb; 20(3):1222-30. PubMed ID: 22249123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of 9-phosphonoalkyl and 9-phosphonoalkoxyalkyl purines: evaluation of their ability to act as inhibitors of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases.
    Česnek M; Hocková D; Holý A; Dračínský M; Baszczyňski O; Jersey Jd; Keough DT; Guddat LW
    Bioorg Med Chem; 2012 Jan; 20(2):1076-89. PubMed ID: 22178188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aza-acyclic nucleoside phosphonates containing a second phosphonate group as inhibitors of the human, Plasmodium falciparum and vivax 6-oxopurine phosphoribosyltransferases and their prodrugs as antimalarial agents.
    Keough DT; Hocková D; Janeba Z; Wang TH; Naesens L; Edstein MD; Chavchich M; Guddat LW
    J Med Chem; 2015 Jan; 58(2):827-46. PubMed ID: 25494538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Evaluation of Novel Acyclic Nucleoside Phosphonates as Inhibitors of Plasmodium falciparum and Human 6-Oxopurine Phosphoribosyltransferases.
    Kaiser MM; Hocková D; Wang TH; Dračínský M; Poštová-Slavětínská L; Procházková E; Edstein MD; Chavchich M; Keough DT; Guddat LW; Janeba Z
    ChemMedChem; 2015 Oct; 10(10):1707-23. PubMed ID: 26368337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acyclic phosph(on)ate inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.
    Clinch K; Crump DR; Evans GB; Hazleton KZ; Mason JM; Schramm VL; Tyler PC
    Bioorg Med Chem; 2013 Sep; 21(17):5629-46. PubMed ID: 23810424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmodium vivax hypoxanthine-guanine phosphoribosyltransferase: a target for anti-malarial chemotherapy.
    Keough DT; Hocková D; Krecmerová M; Cesnek M; Holý A; Naesens L; Brereton IM; Winzor DJ; de Jersey J; Guddat LW
    Mol Biochem Parasitol; 2010 Oct; 173(2):165-9. PubMed ID: 20595032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acyclic immucillin phosphonates: second-generation inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.
    Hazleton KZ; Ho MC; Cassera MB; Clinch K; Crump DR; Rosario I; Merino EF; Almo SC; Tyler PC; Schramm VL
    Chem Biol; 2012 Jun; 19(6):721-30. PubMed ID: 22726686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acyclic Nucleoside Phosphonates Containing 9-Deazahypoxanthine and a Five-Membered Heterocycle as Selective Inhibitors of Plasmodial 6-Oxopurine Phosphoribosyltransferases.
    Kaiser MM; Baszczyňski O; Hocková D; Poštová-Slavětínská L; Dračínský M; Keough DT; Guddat LW; Janeba Z
    ChemMedChem; 2017 Jul; 12(14):1133-1141. PubMed ID: 28628279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unusual substrate specificity of a chimeric hypoxanthine-guanine phosphoribosyltransferase containing segments from the Plasmodium falciparum and human enzymes.
    Sujay Subbayya IN; Sukumaran S; Shivashankar K; Balaram H
    Biochem Biophys Res Commun; 2000 Jun; 272(2):596-602. PubMed ID: 10833458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulfide, sulfoxide and sulfone bridged acyclic nucleoside phosphonates as inhibitors of the Plasmodium falciparum and human 6-oxopurine phosphoribosyltransferases: Synthesis and evaluation.
    Klejch T; Keough DT; Chavchich M; Travis J; Skácel J; Pohl R; Janeba Z; Edstein MD; Avery VM; Guddat LW; Hocková D
    Eur J Med Chem; 2019 Dec; 183():111667. PubMed ID: 31536893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and Evaluation of Asymmetric Acyclic Nucleoside Bisphosphonates as Inhibitors of Plasmodium falciparum and Human Hypoxanthine-Guanine-(Xanthine) Phosphoribosyltransferase.
    Špaček P; Keough DT; Chavchich M; Dračínský M; Janeba Z; Naesens L; Edstein MD; Guddat LW; Hocková D
    J Med Chem; 2017 Sep; 60(17):7539-7554. PubMed ID: 28813147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.
    Gardiner DL; Skinner-Adams TS; Brown CL; Andrews KT; Stack CM; McCarthy JS; Dalton JP; Trenholme KR
    Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1087-98. PubMed ID: 19883329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimalarial activity of prodrugs of N-branched acyclic nucleoside phosphonate inhibitors of 6-oxopurine phosphoribosyltransferases.
    Hocková D; Janeba Z; Naesens L; Edstein MD; Chavchich M; Keough DT; Guddat LW
    Bioorg Med Chem; 2015 Sep; 23(17):5502-10. PubMed ID: 26275679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of novel [3-fluoro-(2-phosphonoethoxy)propyl]purines on the inhibition of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases.
    Baszczyňski O; Hocková D; Janeba Z; Holý A; Jansa P; Dračínský M; Keough DT; Guddat LW
    Eur J Med Chem; 2013 Sep; 67():81-9. PubMed ID: 23850568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel multisubstrate inhibitors of mammalian purine nucleoside phosphorylase.
    Toms AV; Wang W; Li Y; Ganem B; Ealick SE
    Acta Crystallogr D Biol Crystallogr; 2005 Nov; 61(Pt 11):1449-58. PubMed ID: 16239721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a bacterial screen for novel hypoxanthine-guanine phosphoribosyltransferase substrates.
    Shivashankar K; Subbayya IN; Balaram H
    J Mol Microbiol Biotechnol; 2001 Oct; 3(4):557-62. PubMed ID: 11545274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.